NCT05596201

Brief Summary

The goal of this study is to increase magnetic resonance image quality in patients suffering from Parkinson's disease. The main question it aims to answer is: can super-resolution improve clinical magnetic resonance image quality to benefit deep brain stimulation for Parkinson's disease? Participants will receive an additional high-quality MRI scan.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 27, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

March 28, 2023

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 18, 2024

Completed
13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2024

Completed
Last Updated

February 24, 2025

Status Verified

November 1, 2024

Enrollment Period

1.6 years

First QC Date

October 20, 2022

Last Update Submit

February 21, 2025

Conditions

Keywords

Magnetic Resonance ImagingMRISuper Resolution

Outcome Measures

Primary Outcomes (1)

  • Peak signal-to-noise ratio

    The change in image quality as determined by the peak signal-to-noise ratio.

    Six months after study completion of the last subject.

Secondary Outcomes (2)

  • Structural similarity index measure

    Six months after study completion of the last subject.

  • Normalized root mean squared error

    Six months after study completion of the last subject.

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

In the Radboudumc 50-70 bilateral STN-DBS procedures per year are performed for PD. Before being eligible for the DBS procedure, an extensive screening is performed. Any patient that is eligible for the DBS procedure according to this screening is also eligible for this study. From the patients undergoing this procedure, 20 are needed within the current study.

You may qualify if:

  • Patients eligible for bilateral STN-DBS-surgery for Parkinson's disease.
  • Signed informed consent

You may not qualify if:

  • Any intracranial abnormality that is not in line with Parkinson's disease progression
  • Previous intracranial surgery
  • Any significant medical condition that is likely to interfere with study procedures.
  • Pregnancy at the time of enrollment.
  • Participation in any other clinical trial (e.g. drug, device, or biologics) that interferes with this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radboud University Medical Center

Nijmegen, Gelderland, 6525GA, Netherlands

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Saman Vinke, MD

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2022

First Posted

October 27, 2022

Study Start

March 28, 2023

Primary Completion

October 18, 2024

Study Completion

October 31, 2024

Last Updated

February 24, 2025

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

The programs that have been developed, and the models that have been trained, will be published integrally and open source. Such that it is available freely, for the scientific community to use. When the results of this study have been published, the data will be shared open source for use in other research. In this way the data can be used to the fullest. Before sharing the data, the faces will be masked. No identifiable data from subjects will be disclosed. The identity of these subjects can also not be discovered using recombination of this dataset with other datasets.

Locations